期刊文献+

进展性前列腺癌中Fas和Survivin的表达及其相关性研究 被引量:4

Study on expressions and correlation of Fas and Survivin in progressive prostate cancer
下载PDF
导出
摘要 目的:通过检测凋亡相关蛋白Fas、Survivin在进展性前列腺癌(PCa)中的表达及两者的相关性,探讨前列腺癌的发生、发展机制,指导进展性前列腺癌的治疗。方法:应用免疫组化染色(SP)法,检测Fas、Sur-vivin在59例前列腺癌及35例良性前列腺增生(BPH)组织中的表达情况。结果:59例前列腺癌标本中,Fas、Survivin阳性表达率分别是45.8%(27/59)、44.1%(26/59);35例BPH标本中,Fas、Survivin阳性表达率分别是68.6%(24/35)、22.9%(8/35),前列腺癌与BPH组间差异均有显著性意义(P<0.05)。前列腺癌中Sur-vivin表达与病理分级密切相关(P<0.05)。前列腺癌中Fas与Survivin表达呈正相关(r=0.302,P<0.05)。结论:Fas和Survivin在进展性前列腺癌中发生异常表达;联合检测Fas和Survivin蛋白,有助于对进展性前列腺癌细胞的侵袭力作出正确评价,以指导临床治疗。 Objective:By means of detecting the expressions of Fas, Survivin and their correlation in Progressive prostate cancer (PCa) ,we want to investigate the mechanism of development and progression of PCa, and further to guide the endocrine therapy. Methods: Fas, Survivin expressions were assayed in 59 cases of PCa and 35 cases of be- nign prostatic hyperplasia (BPH) by means of immunohistochemistry (SP). Results:The expression of Fas was de- tected in 27 of the 59 cases of progressive PCa and 24 of 35 cases of BPH, and that of Survivin in 26 of the 59 PCa and 8 of the 35 BPH patients. Fas expression was significantly higher in BPH than in cancer tissues (P 〈 0.05 ), and Survivin expression was significantly higher in cancer tissues than in BPH (P 〈 O. 05). The Survivin expression was strongly associated with pathological grades in PCa ( P 〈 0.05 ). A significant correlation was observed between Fas and Survivin expression in PCa( r =0.302,P 〈 0.05). Conclusion-There is abnormal expression of Fas and Survivin in progressive PCa. The detection of Fas and Survivin protein in PCa may help to evaluate the degree of cell apoptosis and decide the therapeutic strategies.
出处 《现代肿瘤医学》 CAS 2009年第1期71-73,共3页 Journal of Modern Oncology
关键词 前列腺癌 FAS SURVIVIN 凋亡 prostate cancer Fas Survivin immunohistochemistry
  • 相关文献

参考文献14

  • 1Clinical Practice Guidelines in Oncology : Prostate Cancer [ J ]. NCCN ,Version 1. 2005.
  • 2Gleason DF. Histologie grading of prostate cancer: a perspective [J].Hum Pathol, 1992,23 ( 3 ) : 273.
  • 3李欣,汪娜,张彦,张舜欣,林倩,唐杰.端粒酶逆转录酶与血管内皮细胞生长因子在前列腺癌中的表达及其相关性的研究[J].中华男科学杂志,2005,11(10):724-726. 被引量:10
  • 4Itoh N, Yonehara S, Ishiia A, et al. The polypeptide encoded by the cDNA for human Cell surface antigen[J]. Fas can mediate apoptosis Cell, 1991,66 (2) :233 - 243.
  • 5Sasaki Y, Ahimed H, Takeuchi T, et al. Immunohistochemical study of Fas, Fas ligand and interleukin - 1β converting enzyme expression in human prostate cancer[ J]. Br J Urol, 1998,81:852.
  • 6史立新,肖序仁,文载律.Fas、FasL在前列腺癌表达的研究[J].解放军医学杂志,2001,26(5):349-351. 被引量:2
  • 7Altieri DC, Marchisio PC. Survivin apoptosis : an interloper between cell death and cell proliferation in cancer[ J]. Lab Invest, 1999, 79 : 1327 - 1333.
  • 8O'Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogensis by Survivin expression in endothelial cells[ J]. 2002,156(2) :393 -398.
  • 9LaCasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis(IAPs) and their emerging role in cancer[J]. Oncogene, 1998, 17(25) :3247 -3259.
  • 10ShinS,Sung BJ, Cho YS,et al. An anti -apoptosis protein human survivin is a direct inhibitor of caspase - 3 and - 7 [ J]. Biochemistry,2001,40(4) :1117 - 1123.

二级参考文献18

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1368
  • 2Scher H,Semin Urol,1992年,10卷,55页
  • 3Jemal A, Murray T, Samules A, et al. Cancer Statistics, 2003[J]. CA Cancer J Clin, 2003, 53 ( 1 ) :5-26.
  • 4Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity[ J ]. EMBO J, 1992,11(5) :1921-1929.
  • 5Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen [ J]. Science,1989, 246(4935 ): 1306-1309.
  • 6Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor ( vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract [ J ].Cancer Res, 1993, 53(19) :4727-4735.
  • 7Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma[J]. J Natl Cancer Inst, 1995, 87(7) :506-516.
  • 8Yoshiji H, Gomez DE, Shibuya M, et al. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer [ J]. Cancer Res, 1996, 56 (9):2013-2016.
  • 9Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine traid expression in colorectal carcinomas and premalignant lesions [J]. Cancer Res, 2000, 60(1) :18-21.
  • 10Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human [ J ]. Science, 1997, 277(5328) :955-959.

共引文献10

同被引文献80

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部